Neuberger Berman Group
ARQT icon

Neuberger Berman Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Neuberger Berman Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-241,846
Closed -$2.3M – 1812
2023
Q2 		$2.3M Buy
241,846
+58,831
+32% +$653K ﹤0.01% 1055
2023
Q1 		$2.01M Buy
183,015
+16,637
+10% +$241K ﹤0.01% 1084
2022
Q4 		$2.46M Buy
166,378
+34,399
+26% +$601K ﹤0.01% 1027
2022
Q3 		$2.52M Sell
131,979
-4,745
-3% -$108K ﹤0.01% 1029
2022
Q2 		$2.91M Buy
136,724
+7,448
+6% +$153K ﹤0.01% 1032
2022
Q1 		$2.49M Buy
129,276
+7,179
+6% +$121K ﹤0.01% 1120
2021
Q4 		$2.53M Buy
122,097
+10
+0% +$199 ﹤0.01% 1136
2021
Q3 		$2.92M Buy
122,087
+871
+0.7% +$19.9K ﹤0.01% 1078
2021
Q2 		$3.3M Buy
121,216
+1,546
+1% +$43.5K ﹤0.01% 1062
2021
Q1 		$3.46M Buy
+119,670
New +$3.74M ﹤0.01% 1034

Other funds holding ARQT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Neuberger Berman Group's ARQT Position: Q3 2023 in Review

Neuberger Berman Group sold out of Arcutis Biotherapeutics (ARQT) in Q3 2023, closing a stake of 241,846 shares — an estimated $2.3M sold.

Neuberger Berman Group first reported a position in ARQT in Q1 2021 and held it in 10 quarters. The position peaked at $3.46M in Q1 2021. 134 funds tracked by Wall St. Rank hold ARQT as of Q3 2023.

  • Neuberger Berman Group reported no remaining Arcutis Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Neuberger Berman Group sold 241,846 Arcutis Biotherapeutics shares in Q3 2023, an estimated $2.3M.
  • Neuberger Berman Group first reported a position in Arcutis Biotherapeutics in Q1 2021 and held it in 10 quarters.
  • Neuberger Berman Group's Arcutis Biotherapeutics position peaked at $3.46M in Q1 2021.
  • 134 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2023.

Based on Neuberger Berman Group's 13F filing for Q3 2023, filed 14 Nov 2023.